KRONOX Lab Sciences Limited has announced its unaudited standalone financial results for the quarter and nine months ended December 31, 2025. The Board of Directors meeting held on February 14, 2026, considered and approved the quarterly financial performance under SEBI Regulation 33.

Q3FY26 Financial Performance

The company demonstrated steady performance in the third quarter with consistent revenue generation and profitability. The quarterly results show the company's operational efficiency in its specialty fine chemicals manufacturing business.

Nine Months Performance Overview

For the nine months ended December 31, 2025, KRONOX Lab Sciences maintained robust financial performance across key metrics. The cumulative results demonstrate sustained growth momentum.

Board Meeting and Regulatory Compliance

The Board of Directors meeting commenced at 2:00 PM and concluded at 2:30 PM on Saturday, February 14, 2026. The board considered and approved the standalone unaudited financial results along with the Independent Auditors' Limited Review Report on Financial Results.

Business Operations

KRONOX Lab Sciences operates in the specialty fine chemicals segment, which represents the company's single reportable segment under Ind AS-108 on Operating Segments. The company focuses on manufacturing high purity specialty fine chemicals from its facilities in Gujarat.

Auditor Review

Mahesh Udhwani & Associates, Chartered Accountants, conducted the limited review of the unaudited financial results. The review was performed in accordance with Standard on Review Engagements (SRE) 2410, and the auditors found no material misstatements in the financial results prepared under applicable accounting standards.

Kronox Lab Sciences , a manufacturer of high-purity specialty fine chemicals, has announced its financial results for the quarter and half-year ended September 30, 2025, showing strong performance in both revenue and profit.

Financial Highlights

The company reported significant figures for both the quarter and half-year periods. Here's a breakdown of the key financial metrics:

Revenue and Profit Analysis

Kronox Lab Sciences' revenue from operations for the quarter reached ₹2,553.32 lakhs, while the half-year figure stood at ₹4,981.97 lakhs. This performance indicates strong demand for the company's high-purity specialty fine chemicals.

The company's profit after tax for the quarter was ₹1,129.96 lakhs, with the half-year figure reaching ₹2,546.70 lakhs. These profit figures suggest that Kronox Lab Sciences has maintained operational efficiency and cost management.

Corporate Developments

• The Board of Directors approved the standalone unaudited financial results during their meeting.
• Kronox Lab Sciences operates in the manufacturing of high purity specialty fine chemicals as its single reportable segment.
• The company had completed its IPO, which was a 100% Offer for Sale (OFS).
• A final dividend of 5% for FY24-25 was declared and paid out in September 2025.

Audit and Review

The financial results were reviewed by statutory auditors and recommended by the audit committee, ensuring compliance with regulatory requirements and maintaining transparency in financial reporting.

Conclusion

Kronox Lab Sciences' financial results for the quarter and half-year ended September 30, 2025, demonstrate strong performance in both revenue generation and profitability. The company's profit levels suggest effective cost management and operational efficiency. As Kronox Lab Sciences continues to operate in the specialty chemicals market, investors and stakeholders will be watching closely to see how the company performs in the high-purity specialty fine chemicals sector.